中信证券股份有限公司 关于新奥天然气股份有限公司发行股份及支付现金购买资产暨关联 交易限售股解禁上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券" "独立财务顾问"）作为新奥 天然气股份有限公司（以下简称"新奥股份" "上市公司"或"公司"）发行股份 及支付现金购买新奥（舟山）液化天然气有限公司 90%股权（以下简称"标的资 产"）暨关联交易（以下简称"本次交易"）的独立财务顾问，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司证券发行注册管理办法》《上 市公司重大资产重组管理办法》 《上市公司并购重组财务顾问业务管理办法》 《上 海证券交易所股票上市规则》等有关规定和要求，对新奥股份本次交易发行股份 购买资产部分限售股解禁并上市流通事项进行了核查，具体核查情况如下： 一、本次限售股上市类型 本次限售股上市流通类型为发行股份购买资产限售股，具体情况如下： （一）股票发行的核准情况 新奥股份以发行股份及支付现金相结合的方式购买新奥科技发展有限公司 （以下简称"新奥科技"）、新奥集团股份有限公司（以下简称"新奥集团"）和 新奥控股投资股份有限公司（以下简称"新奥控股"）持有的新奥（舟山 ...

Core Insights - On August 12, a total of 6 companies had their restricted shares unlocked, with a total unlock volume of 1.45 billion shares, amounting to a market value of 195.817 billion yuan based on the latest closing price [1] Summary by Category Unlock Volume - One company had an unlock volume exceeding 10 million shares [1] - The companies with the highest unlock volumes were Haiguang Information, Qushui Technology, and Yongtai Technology, with unlock volumes of 1.438 billion shares, 4.6837 million shares, and 4.4548 million shares respectively [1] Unlock Market Value - One company had an unlock market value exceeding 100 million yuan [1] - The companies with the highest unlock market values were Haiguang Information, Qushui Technology, and Yongtai Technology, with market values of 195.409 billion yuan, 27 million yuan, and 6.2378 million yuan respectively [1] Unlock Ratio - Two companies had an unlock ratio exceeding 10% of their total share capital [1] - The companies with the highest unlock ratios were Haiguang Information, Qushui Technology, and Liansheng Technology, with ratios of 61.86%, 11.71%, and 0.55% respectively [1]

（原标题：今日看点｜恒生港股通创新药指数修订方案生效） 8月11日重点关注的财经要闻与资本市场大事： 1、恒生港股通创新药指数修订方案今起生效 8月11日，1家公司共发布1个股票回购相关进展。其中，1家公司首次披露股票回购预案。从首次披露回 购预案来看，当日共1家公司股票回购预案金额超千万。佰维存储回购预案金额最高，拟回购不超 4000.0万元。 4、今日有5448亿元7天期逆回购到期 8月4日，央行开展5448亿元7天期逆回购操作，操作利率1.4%，今日到期。 5、意大利7月CPI、墨西哥6月工业产值等数据将公布。 （数据来源Wind，内容不构成任何投资建议） 近日，恒生港股通创新药指数宣布修订编制方案，明确剔除CXO公司，聚焦创新药核心公司，修订规 则8月11日生效，该指数将成为ETF跟踪的指数中首批"纯度"达100%的创新药指数。 2、144.91亿元市值限售股今日解禁 8月11日，共有15家公司限售股解禁，合计解禁量为4.39亿股，按最新收盘价计算，合计解禁市值为 144.91亿元。 从解禁量来看，6家公司解禁股数超千万股。亚信安全、满坤科技、德科立解禁量居前，解禁股数分别 为1.91亿股、1.02亿 ...

Group 1 - Beijing has lifted housing purchase restrictions outside the Fifth Ring Road, effective from August 9, leading to a 20%-30% increase in property viewings [2] - The new policy includes adjustments to housing provident fund policies, allowing a maximum loan of 1.4 million yuan for second homes and reducing the required contribution period [2] - Industrial Fulian reported a revenue of approximately 360.76 billion yuan for the first half of the year, a year-on-year increase of 35.58%, with a net profit of about 12.11 billion yuan, up 38.61% [10] Group 2 - This week, 34 companies will have a total of 3.057 billion shares released from lock-up, with a total market value of 232.51 billion yuan based on the latest closing prices [12] - The companies with the highest market value of released shares include Haiguang Information, Zhiwei Intelligent, and Guoxin Securities [12] - A new stock, Hongyuan Co., will be issued on August 11, with a subscription code of 920018 and an issue price of 9.17 yuan [15]

Core Viewpoint - The unlocking of restricted shares for Sanyuan Biotech is a significant event, as it involves 92.946 million shares, accounting for 45.94% of the total share capital, which may impact market dynamics and investor sentiment [2][3][4]. Share Unlocking Details - Sanyuan Biotech announced that 92.946 million shares will be unlocked on August 11, representing 45.94% of the total share capital, primarily held by the controlling shareholder, Nie Zaijian [2][3]. - Out of the unlocked shares, 22.6719 million shares will be available for trading, while 70.2741 million shares will remain locked [3]. Shareholder Actions - In July, Sanyuan Biotech disclosed that shareholder Luxin Capital plans to reduce its holdings by up to 6 million shares within three months, raising concerns about the overall share liquidity [4]. Market Stability Measures - To stabilize market confidence amid the unlocking and potential shareholder sell-offs, Sanyuan Biotech's board approved a share buyback plan with a budget of 50 million to 100 million yuan [4]. Industry Challenges - Sanyuan Biotech faces challenges due to its reliance on international markets, with 70.70% of its revenue coming from exports in 2024 [6]. - The company is currently subject to a preliminary anti-dumping duty of 450.64% imposed by the U.S. Department of Commerce, which could significantly impact its sales in the U.S. market [6]. Product Structure Concerns - The company's product structure is heavily reliant on erythritol, which accounted for 72.30% of its revenue in 2024, making it vulnerable to market fluctuations [7]. - Sanyuan Biotech plans to diversify its product offerings and enhance R&D to mitigate risks associated with its current product concentration [7]. Market Conditions - The erythritol market has experienced significant price fluctuations, with prices dropping from 40,000 yuan/ton in 2021 to as low as 9,500 yuan/ton in the first half of 2023, affecting production incentives [7]. - The industry is currently in a phase of cyclical volatility, with excess capacity still a concern, although market mechanisms may lead to consolidation and improved conditions for efficient producers [7]. Future Outlook - Sanyuan Biotech is at a critical juncture, facing both internal and external pressures, and its ability to navigate these challenges for sustainable growth remains to be seen [8].

Core Viewpoint - The recent announcement by Sanyuan Biological regarding the lifting of restrictions on a significant portion of its shares has raised concerns among investors, particularly in light of the company's operational challenges and reliance on international markets [2][3][6]. Group 1: Share Unlocking and Market Impact - Sanyuan Biological will unlock 92.946 million shares, accounting for 45.94% of its total share capital, on August 11, with 22.672 million shares available for trading [2][3]. - The company is facing additional market pressure as other shareholders, such as Luxin Capital, plan to reduce their holdings by up to 6 million shares [3]. - The unlocking of shares is expected to increase the total supply in the market, potentially leading to short-term stock price volatility, especially for companies with weaker fundamentals [5]. Group 2: Financial Performance and Challenges - Sanyuan Biological has experienced fluctuating performance, with revenues of 675 million yuan, 500 million yuan, and 713 million yuan from 2022 to 2024, and net profits of 164 million yuan, 56 million yuan, and 105 million yuan during the same period [5][6]. - The company heavily relies on international markets, with 70.70% of its main business revenue coming from exports in 2024 [6]. - The U.S. Department of Commerce has imposed a preliminary anti-dumping duty of 450.64% on Sanyuan Biological, which is expected to impact its sales in the U.S. market [6]. Group 3: Product Structure and Market Conditions - Sanyuan Biological's product structure is relatively singular, with erythritol revenue constituting 72.30% of total revenue in 2024 [7]. - The company acknowledges that fluctuations in the erythritol market or failures in new product development could adversely affect its performance [7]. - The erythritol market has seen significant price declines, with prices dropping from a peak of 40,000 yuan/ton in 2021 to as low as 9,500 yuan/ton in the first half of 2023, leading to reduced production and market exits by some companies [7]. Group 4: Strategic Responses - In response to market pressures, Sanyuan Biological has initiated a share buyback program, aiming to repurchase shares worth between 50 million and 100 million yuan [4]. - As the company navigates internal and external pressures, its ability to adapt and achieve sustainable growth remains to be seen [8].

Core Viewpoint - The recent announcement by Sanyuan Bio regarding the lifting of restrictions on a significant portion of its shares has raised concerns among investors, particularly in light of the company's operational challenges and reliance on international markets [2][3][5]. Share Unlocking and Market Impact - Sanyuan Bio will unlock 92.946 million shares on August 11, representing 45.94% of its total share capital, primarily held by the controlling shareholder, Nie Zaijian [2][3]. - Out of the unlocked shares, 22.6719 million shares will be available for trading, while 70.2741 million shares will remain locked [3]. - The company has also disclosed that another shareholder, Luxin Capital, plans to reduce its holdings by up to 6 million shares within three months, further intensifying market scrutiny [3]. Market Confidence and Stock Buyback - In response to the potential market pressure from the share unlock and shareholder reductions, Sanyuan Bio has initiated measures to stabilize market confidence, including a share buyback plan with a budget of 50 million to 100 million yuan [4]. - As of July 8, 2025, the company has repurchased approximately 2.33 million shares, accounting for 1.15% of its total share capital, with a total expenditure of about 60.68 million yuan [4]. Operational Challenges - Sanyuan Bio has faced operational challenges, including a significant reliance on international markets, with 70.70% of its revenue coming from exports in 2024 [6]. - The company has experienced revenue fluctuations, with reported revenues of 675 million yuan in 2022, 500 million yuan in 2023, and 713 million yuan in 2024, alongside net profits of 164 million yuan, 56 million yuan, and 105 million yuan for the same years [6]. - The recent imposition of a 450.64% anti-dumping duty by the U.S. Department of Commerce poses additional challenges for the company's sales in the U.S. market [6][7]. Product Structure and Market Dynamics - Sanyuan Bio's product structure is heavily reliant on erythritol, which accounted for 72.30% of its revenue in 2024, raising concerns about vulnerability to market fluctuations [8]. - The erythritol market has experienced significant price volatility, with prices dropping from a peak of 40,000 yuan per ton in 2021 to as low as 9,500 yuan per ton in the first half of 2023 [8]. - The industry is currently in a phase of cyclical volatility, with excess capacity still a concern, although market mechanisms are expected to lead to consolidation and a more favorable competitive landscape for efficient producers [8]. Future Outlook - Sanyuan Bio is at a critical juncture, facing both internal and external pressures, and its ability to navigate these challenges and achieve sustainable growth remains to be seen [9].

Core Viewpoint - The report outlines the verification opinion of CITIC Construction Investment Securities Co., Ltd. regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Zhejiang Haizheng Biological Materials Co., Ltd. on the Sci-Tech Innovation Board, confirming compliance with relevant regulations and the accuracy of information disclosure [1][8]. Summary by Sections Type of Restricted Shares - The restricted shares being listed are part of the company's IPO, totaling 50,669,517 shares, which were listed on August 16, 2022. The total share capital after the IPO is 202,678,068 shares, with restricted shares accounting for 156,470,896 shares (77.20%) and unrestricted shares for 46,207,172 shares (22.80%) [1]. Shareholder Information - The restricted shares involve three shareholders: Taizhou Jiaojiang Chuanghe Enterprise Management Partnership (Limited Partnership), Taizhou Jiaojiang Chuangyou Enterprise Management Partnership (Limited Partnership), and Taizhou Chuangyi Enterprise Management Service Center (Limited Partnership), holding a total of 6,390,100 shares, representing 3.15% of the current total share capital. The lock-up period for these shares is 36 months from the listing date, expiring on August 16, 2025, with the actual listing date adjusted to August 18, 2025, due to a non-trading day [2][3]. Changes in Share Capital - Since the formation of the restricted shares, there have been no changes in the company's share capital due to profit distribution or capital increase [2]. Commitments by Shareholders - The shareholders have committed not to transfer or manage their shares for 36 months post-listing and to comply with relevant regulations during any future share reductions. Any income from violations will be returned to the company [3][4]. Lock-up Period Extension - The lock-up period for certain shareholders was automatically extended by six months to February 15, 2026, due to the stock price falling below the IPO price for 20 consecutive trading days [5][7]. Total Restricted Shares for Listing - The total number of restricted shares for listing is 6,390,100 shares, with the listing date set for August 18, 2025 [7]. Verification Opinion - The sponsor institution confirms that the listing of the restricted shares complies with the Company Law, Securities Law, and relevant regulations, and that the information disclosure is true, accurate, and complete [8].

周三（8月6日），共有7家公司限售股解禁，合计解禁量为1614.08万股，按最新收盘价计算，合计解禁 市值为6.65亿元。从解禁量来看，龙图光罩、飞鹿股份、安集科技解禁量居前，解禁股数分别为830.45 万股、578.63万股、54.86万股。从解禁市值来看，0家公司解禁股数超亿元。龙图光罩、恒玄科技、安 集科技解禁市值居前，解禁市值分别为3.85亿元、9929.21万元、8223.41万元。从解禁股数占总股本比 例来看，龙图光罩、飞鹿股份、安集科技解禁比例居前，解禁比例分别为6.22%、2.74%、0.33%。 ...

Group 1 - The core viewpoint of the article is that Guotai Junan Securities Co., Ltd. has conducted a review of the restricted shares of Beikong Technology Co., Ltd. that are set to be released for trading following a major asset restructuring transaction [1][9] - The type of restricted shares being listed for circulation is related to the issuance of shares and cash payment for asset acquisition, along with the fundraising for the associated transaction [1] - The company received approval from the China Securities Regulatory Commission on July 4, 2022, to issue shares for asset acquisition and to raise no more than 68 million yuan [1] Group 2 - A total of 12,117,610 new shares were registered with the China Securities Depository and Clearing Corporation on August 10, 2022 [2] - The lock-up period for the newly issued shares is set for 36 months from the date of issuance, during which the shares cannot be transferred [2][3] - The total share capital of the company has increased to 184,945,734 shares following the completion of the share issuance and registration [2] Group 3 - The controlling shareholder, Minmetals Technology Group Co., Ltd., and other related parties have made commitments regarding the lock-up period for the shares, agreeing to not transfer the shares for 36 months [3][4] - All parties involved have adhered to their commitments regarding the restricted shares, and there are no violations affecting the circulation of these shares [5] - The number of restricted shares being released for trading is 12,117,610 shares [5] Group 4 - The share structure before and after the release of restricted shares shows a decrease in restricted shares from 13,586,320 to 1,468,710, while unrestricted shares increased from 175,677,206 to 187,794,816 [7] - The independent financial advisor has confirmed that the release of restricted shares complies with relevant laws and regulations [8]